Critical care niche Leverage IKARIAs focus on critical care and its lead INOMAX therapy to target hospitals with NICU capabilities and neonatal respiratory care programs, presenting bundled solutions that combine drug, delivery system, and 24/7 support.

Global reach Target markets where INOMAX is marketed (USA, Puerto Rico, Canada, Australia, Mexico, Japan) for cross-sell of related critical care products or companion devices, and explore expansion partnerships in allied regional distributors.

Financial potential With substantial revenue scale and a sizable funding backdrop, approach large pediatric and neonatal wards, academic medical centers, and government-funded healthcare procurement channels for negotiated contracts and long-term supply agreements.

Key decision makers Engage hospital procurement, neonatal ICU leadership, and respiratory therapy directors who influence purchasing of inhaled nitric oxide therapy packages, offering on-site training and 24/7 support as value differentiators.

Service advantage Highlight the all-inclusive INOMAX therapy package as a differentiator in competitive bids, emphasizing training, on-site support, and continuous technical assistance to reduce deployment risk and ensure consistent patient care outcomes.